P-0214 Hypertension as A Predictive Biomarker in Bevacizumab
نویسندگان
چکیده
منابع مشابه
Substance P as a potential biomarker of pain assessment in dogs
Background: Substance P (SP) is a neuropeptide that functions as a neuromodulator. It is released mainly in the brain stem and in nerve endings. Aims: The present study aimed to provide fundamental data that may be applied to the assessment of pain in dogs by evaluating their serum SP concentrations. Methods: Two groups of dogs were designated ...
متن کاملApelin: A putative novel predictive biomarker for bevacizumab response in colorectal cancer
Bevacizumab (bvz) is currently employed as an anti-angiogenic therapy across several cancer indications. Bvz response heterogeneity has been well documented, with only 10-15% of colorectal cancer (CRC) patients benefitting in general. For other patients, clinical efficacy is limited and side effects are significant. This reinforces the need for a robust predictive biomarker of response. To iden...
متن کاملRelative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma.
BACKGROUND To analyze the relevance of dynamic susceptibility-weighted contrast-enhanced MRI (DSC-MRI) derived relative cerebral blood volume (rCBV) analysis for predicting response to bevacizumab (BEV) in patients with recurrent glioblastoma (rGB). METHODS A total of 127 patients diagnosed with rGB receiving either bevacizumab (71 patients, BEV cohort) or alkylating chemotherapy (56 patients...
متن کاملDR6 as a Diagnostic and Predictive Biomarker in Adult Sarcoma
BACKGROUND The Death Receptor 6 (DR6) protein is elevated in the serum of ovarian cancer patients. We tested DR6 serum protein levels as a diagnostic/predictive biomarker in several epithelial tumors and sarcomas. METHODS DR6 gene expression profiles were screened in publically available arrays of solid tumors. A quantitative immunofluorescent western blot analysis was developed to test the s...
متن کاملPD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy.
The resurgence of cancer immunotherapy stems from an improved understanding of the tumor microenvironment. The PD-1/PD-L1 axis is of particular interest, in light of promising data demonstrating a restoration of host immunity against tumors, with the prospect of durable remissions. Indeed, remarkable clinical responses have been seen in several different malignancies including, but not limited ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Oncology
سال: 2012
ISSN: 0923-7534
DOI: 10.1016/s0923-7534(20)30139-3